Predictive Historical Income Statement

POAI Stock

USD 0.81 0.03 3.85%

Historical analysis of Predictive Oncology income statement accounts such as Other Operating Expenses of 9.6 M, Total Operating Expenses of 9.3 M, Income Tax Expense of 3.8 or Total Revenue of 899.7 K can show how well Predictive Oncology performed in making a profits. Evaluating Predictive Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Predictive Oncology's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Predictive Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Predictive Oncology is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.

About Predictive Income Statement Analysis

Predictive Oncology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Predictive Oncology shareholders. The income statement also shows Predictive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Predictive Oncology Income Statement Chart

As of now, Predictive Oncology's Depreciation And Amortization is increasing as compared to previous years. The Predictive Oncology's current Interest Expense is estimated to increase to about 12.9 M, while Selling General Administrative is projected to decrease to under 7.1 M.

Selling General Administrative Selling And Marketing Expenses Other Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Predictive Oncology. It is also known as Predictive Oncology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Predictive Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Predictive Oncology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.As of now, Predictive Oncology's Depreciation And Amortization is increasing as compared to previous years. The Predictive Oncology's current Interest Expense is estimated to increase to about 12.9 M, while Selling General Administrative is projected to decrease to under 7.1 M.

	2021	2022	2023	2024 (projected)
Gross Profit	933.7K	1.0M	1.1M	575.4K
Total Revenue	1.4M	1.5M	1.8M	899.7K

Gross Profit Total Revenue

Predictive Oncology income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Research Development	Net Income From Continuing Ops	Reconciled Depreciation	Interest Income	Non Recurring	Non Operating Income Net Other
Depreciation And Amortization		0.01	0.42	0.46	0.5	-0.44	-0.49	0.05	0.5	-0.5	0.5	0.41	0.38	0.46	-0.46	-0.35	0.7	-0.45	0.35	0.52	0.02	-0.03
Interest Expense	0.01		0.52	0.2	0.59	-0.74	-0.69	-0.79	0.59	-0.35	0.02	0.56	0.55	0.55	-0.51	-0.2	-0.29	-0.63	0.78	0.68	-0.66	0.65
Selling General Administrative	0.42	0.52		0.34	0.94	-0.64	-0.92	-0.79	0.94	-0.81	0.58	0.7	0.68	0.71	-0.88	-0.65	0.32	-0.78	0.79	0.79	-0.1	0.2
Selling And Marketing Expenses	0.46	0.2	0.34		0.58	-0.56	-0.52	-0.31	0.57	-0.35	0.13	0.79	0.81	0.72	-0.39	-0.19	0.57	-0.41	0.29	0.37	-0.12	0.23
Other Operating Expenses	0.5	0.59	0.94	0.58		-0.72	-0.96	-0.79	1.0	-0.84	0.57	0.88	0.87	0.87	-0.91	-0.67	0.43	-0.86	0.85	0.89	-0.16	0.32
Operating Income	-0.44	-0.74	-0.64	-0.56	-0.72		0.77	0.62	-0.72	0.37	-0.07	-0.63	-0.62	-0.62	0.5	0.1	0.0	0.52	-0.6	-0.59	0.42	-0.44
Ebit	-0.49	-0.69	-0.92	-0.52	-0.96	0.77		0.85	-0.96	0.82	-0.53	-0.82	-0.81	-0.82	0.9	0.6	-0.36	0.9	-0.88	-0.89	0.39	-0.41
Ebitda	0.05	-0.79	-0.79	-0.31	-0.79	0.62	0.85		-0.79	0.63	-0.3	-0.69	-0.69	-0.65	0.75	0.47	0.01	0.76	-0.79	-0.7	0.47	-0.5
Total Operating Expenses	0.5	0.59	0.94	0.57	1.0	-0.72	-0.96	-0.79		-0.84	0.57	0.87	0.86	0.86	-0.91	-0.67	0.43	-0.86	0.85	0.89	-0.16	0.32
Net Income	-0.5	-0.35	-0.81	-0.35	-0.84	0.37	0.82	0.63	-0.84		-0.89	-0.68	-0.67	-0.68	0.97	0.93	-0.58	0.92	-0.83	-0.81	0.02	-0.01
Income Tax Expense	0.5	0.02	0.58	0.13	0.57	-0.07	-0.53	-0.3	0.57	-0.89		0.38	0.36	0.41	-0.77	-0.85	0.57	-0.7	0.56	0.59	0.17	-0.17
Total Revenue	0.41	0.56	0.7	0.79	0.88	-0.63	-0.82	-0.69	0.87	-0.68	0.38		0.99	0.97	-0.76	-0.55	0.49	-0.78	0.75	0.8	-0.21	0.4
Gross Profit	0.38	0.55	0.68	0.81	0.87	-0.62	-0.81	-0.69	0.86	-0.67	0.36	0.99		0.94	-0.75	-0.55	0.48	-0.77	0.73	0.77	-0.2	0.39
Cost Of Revenue	0.46	0.55	0.71	0.72	0.87	-0.62	-0.82	-0.65	0.86	-0.68	0.41	0.97	0.94		-0.75	-0.53	0.48	-0.76	0.74	0.82	-0.22	0.42
Income Before Tax	-0.46	-0.51	-0.88	-0.39	-0.91	0.5	0.9	0.75	-0.91	0.97	-0.77	-0.76	-0.75	-0.75		0.88	-0.51	0.96	-0.91	-0.87	0.12	-0.12
Total Other Income Expense Net	-0.35	-0.2	-0.65	-0.19	-0.67	0.1	0.6	0.47	-0.67	0.93	-0.85	-0.55	-0.55	-0.53	0.88		-0.56	0.81	-0.74	-0.67	-0.22	0.23
Research Development	0.7	-0.29	0.32	0.57	0.43	0.0	-0.36	0.01	0.43	-0.58	0.57	0.49	0.48	0.48	-0.51	-0.56		-0.46	0.24	0.37	0.19	-0.2
Net Income From Continuing Ops	-0.45	-0.63	-0.78	-0.41	-0.86	0.52	0.9	0.76	-0.86	0.92	-0.7	-0.78	-0.77	-0.76	0.96	0.81	-0.46		-0.95	-0.93	0.32	-0.31
Reconciled Depreciation	0.35	0.78	0.79	0.29	0.85	-0.6	-0.88	-0.79	0.85	-0.83	0.56	0.75	0.73	0.74	-0.91	-0.74	0.24	-0.95		0.93	-0.32	0.34
Interest Income	0.52	0.68	0.79	0.37	0.89	-0.59	-0.89	-0.7	0.89	-0.81	0.59	0.8	0.77	0.82	-0.87	-0.67	0.37	-0.93	0.93		-0.33	0.48
Non Recurring	0.02	-0.66	-0.1	-0.12	-0.16	0.42	0.39	0.47	-0.16	0.02	0.17	-0.21	-0.2	-0.22	0.12	-0.22	0.19	0.32	-0.32	-0.33		-0.8
Non Operating Income Net Other	-0.03	0.65	0.2	0.23	0.32	-0.44	-0.41	-0.5	0.32	-0.01	-0.17	0.4	0.39	0.42	-0.12	0.23	-0.2	-0.31	0.34	0.48	-0.8

Click cells to compare fundamentals

Predictive Oncology Account Relationship Matchups

Predictive Oncology income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	8.9M	1.0M	1.3M	1.3M	739.3K	954.9K
Selling General Administrative	9.8M	10.4M	10.9M	11.1M	9.4M	7.1M
Selling And Marketing Expenses	1.9M	584.9K	774.5K	1.4M	1.5M	913.9K
Other Operating Expenses	15.2M	13.7M	14.9M	16.8M	15.7M	9.6M
Operating Income	(13.8M)	(666.3K)	(13.5M)	(15.3M)	(13.9M)	(13.2M)
Ebit	(13.8M)	(12.5M)	(13.5M)	(15.3M)	(13.9M)	(13.2M)
Ebitda	(4.9M)	(11.5M)	(12.1M)	(14.0M)	(13.2M)	(12.5M)
Total Operating Expenses	14.7M	13.3M	14.4M	16.3M	15.1M	9.3M
Net Income	(27.6M)	(37.7M)	(19.7M)	(36.2M)	(14.0M)	(14.7M)
Income Tax Expense	8.2M	11.8M	(661.7K)	10.5M	4.0	3.8
Total Revenue	1.4M	1.3M	1.4M	1.5M	1.8M	899.7K
Gross Profit	879.8K	805.1K	933.7K	1.0M	1.1M	575.4K
Cost Of Revenue	531.8K	447.2K	487.0K	505.1K	634.8K	324.3K
Income Before Tax	(19.4M)	(25.9M)	(20.3M)	(25.7M)	(14.0M)	(14.7M)
Total Other Income Expense Net	(5.6M)	(13.4M)	(6.8M)	(10.5M)	(62.6K)	(65.8K)
Research Development	3.0M	2.4M	315.9K	320.3K	188.3K	178.9K
Net Income From Continuing Ops	(19.4M)	(25.9M)	(19.7M)	(25.7M)	(18.4M)	(19.3M)
Net Income Applicable To Common Shares	(19.7M)	(26.4M)	(19.7M)	(25.7M)	(23.2M)	(24.3M)
Reconciled Depreciation	704.9K	1.0M	1.3M	1.3M	913.7K	866.8K

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:

How To Invest In Predictive

Details

Is Predictive Stock a good investment?

Details

What is Predictive Oncology's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.

You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.96)

Revenue Per Share

0.416

Quarterly Revenue Growth

(0.43)

Return On Assets

(0.56)

Return On Equity

(1.49)

The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Predictive Historical Income Statement

About Predictive Income Statement Analysis

Predictive Oncology Income Statement Chart

Other Operating Expenses

Predictive Oncology income statement Correlations

Predictive Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Predictive Oncology income statement Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Gross Profit	+ 0.99	Total Revenue
Income Before Tax	+ 0.97	Net Income
Cost Of Revenue	+ 0.97	Total Revenue
Net Income From Continuing Ops	+ 0.96	Income Before Tax
Other Operating Expenses	+ 0.94	Selling General Administrative

Total Operating Expenses	- 0.96	Ebit
Ebit	- 0.96	Other Operating Expenses
Reconciled Depreciation	- 0.95	Net Income From Continuing Ops
Interest Income	- 0.93	Net Income From Continuing Ops
Ebit	- 0.92	Selling General Administrative
Reconciled Depreciation	- 0.91	Income Before Tax